Search research articles
Contact Us
Filters
Showing results (161-170 of 203) with videos related to
Page
of 21
Sort By:
Chemotherapy
|
April 28, 2024
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden
James Alexander Korolewicz, Bernhard Scheiner, Claudia A M Fulgenzi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 19, 2026
Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma-Data From the Multinational LITCHI Registry
Ulrike Bauer, Maria R Troppmair, Najib Ben Khaled, et al.
Wiener Klinische Wochenschrift
|
June 26, 2023
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)
Mattias Mandorfer, Elmar Aigner, Manfred Cejna, et al.
Annals of Hepatology
|
August 15, 2024
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma
Louisa Stern, Constantin Schmidt, Lorenz Kocheise, et al.
Journal of Hepatology
|
December 6, 2021
HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease
Georg Semmler, Elias Laurin Meyer, Karin Kozbial, et al.
JAMA Oncology
|
August 24, 2023
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Enrui Xie, Yee Hui Yeo, Bernhard Scheiner, et al.
JHEP Reports : Innovation in Hepatology
|
July 18, 2025
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
JHEP Reports : Innovation in Hepatology
|
April 30, 2026
Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC
Najib Ben Khaled, Raphael Mohr, Leonie S Jochheim, et al.
Annals of Hepatology
|
October 13, 2025
Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab
Lorenz Kocheise, Jan Kempski, Yunhe Tang, et al.
Hepatology International
|
April 3, 2023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 203) with videos related to
Sort By:
Page
of 21
Chemotherapy
|
April 28, 2024
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden
James Alexander Korolewicz, Bernhard Scheiner, Claudia A M Fulgenzi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 19, 2026
Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma-Data From the Multinational LITCHI Registry
Ulrike Bauer, Maria R Troppmair, Najib Ben Khaled, et al.
Wiener Klinische Wochenschrift
|
June 26, 2023
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)
Mattias Mandorfer, Elmar Aigner, Manfred Cejna, et al.
Annals of Hepatology
|
August 15, 2024
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma
Louisa Stern, Constantin Schmidt, Lorenz Kocheise, et al.
Journal of Hepatology
|
December 6, 2021
HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease
Georg Semmler, Elias Laurin Meyer, Karin Kozbial, et al.
JAMA Oncology
|
August 24, 2023
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Enrui Xie, Yee Hui Yeo, Bernhard Scheiner, et al.
JHEP Reports : Innovation in Hepatology
|
July 18, 2025
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
JHEP Reports : Innovation in Hepatology
|
April 30, 2026
Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC
Najib Ben Khaled, Raphael Mohr, Leonie S Jochheim, et al.
Annals of Hepatology
|
October 13, 2025
Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab
Lorenz Kocheise, Jan Kempski, Yunhe Tang, et al.
Hepatology International
|
April 3, 2023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Page
of 21